



## MIB Agents OutSmarting Osteosarcoma 2024 Grant Program Guidelines

### About MIB Agents

MIB Agents is a leading pediatric osteosarcoma nonprofit dedicated to Making It Better for our community of patients, families, medical professionals, researchers, and industry partners through programs, education, and research. We are devoted to creating and instilling hope with and for our inclusive and collaborative osteosarcoma community. We do this through mutual trust, transparency and compassion.

### About the MIB Agents OutSmarting Osteosarcoma Grant Program

The OutSmarting Osteosarcoma Research Grant is an annual award begun in 2017. Since then, MIB Agents has supported 18 investigators and awarded \$1,550,000 to support osteosarcoma research.

Collaboration among the scientific and patient communities is a key hallmark of MIB Agents. MIB Agents OutSmarting Osteosarcoma grants are supported by MIB Agents Family Funds, osteosarcoma patients, and families who raise funds in honor of an OsteoWarrior or OsteoAngel. Their dedication to Making It Better and fostering collaboration and education in the scientific community makes every MIB Agents award incredibly meaningful.

### About the MIB Agents OutSmarting Osteosarcoma 2024 Awards

For 2024, MIB Agents is thrilled to offer two funding mechanisms.

The OutSmarting Osteosarcoma Research Award is a \$100,000 grant over one year to any investigator with a compelling study that will Make It Better for osteosarcoma patients.

The OutSmarting Osteosarcoma Young Investigator (YI) Research Award is a \$50,000 grant over one year to any young investigator with a compelling study that will Make It Better for osteosarcoma patients.

Awards may be sponsored by one MIB Agents Family Fund or individual donor, which is co-branded in honor of the Family Fund.

The number of grants by award type will be determined based on budget and program goals during programmatic review.



## **MIB Agents OutSmarting Osteosarcoma 2024 Grant Program Guidelines**

### **Funding Priorities**

To have the most immediate impact on patient care, MIB Agents funding priorities are:

- Late stage translational research - probability of an advance in the near-term; research may lead to a clinical trial in one to three years.
- Studies with promising preclinical data that have a specific funding need to move forward to clinical trial.
- Specific funding gaps in clinical research. Examples include correlative studies associated with and/or prior to an already funded clinical trial.
- Projects that facilitate and enhance collaboration and shared learnings.

### **Focus Areas**

Proposals should address at least one of these focus areas:

- Children, adolescents & young adults
- Decreasing toxicities
- Immunotherapies
- Molecularly targeted therapiesGenome informed precision medicine
- Preventing metastasis
- Systemic therapy combinations
- Treating recurrent disease

### **Review Process and Evaluation Criteria**

Proposals are evaluated with a two-tier review process. First, proposals undergo independent peer review by the MIB Agents Scientific Review Committee and are scored based on scientific merit. Family Funds and donors contributing more than \$5,000 to the annual award are invited to participate in the review process as stakeholder reviewers, scoring proposals on patient impact. The Scientific Review Committee is composed of the MIB Agents Scientific Advisory Board, external reviewers as needed, and Family Fund stakeholder reviewers.

Proposals scoring above a predetermined threshold are eligible for funding and will be required to present their proposed work via video conference call with the MIB Research Advisory Committee and all MIB Agents Family Funds. After applicants have had the opportunity to share their proposal with the MIB Agents community, the proposals move onto Programmatic Review, where grant recipients will be selected by the MIB Research Advisory Committee based on scientific review recommendations, how well the proposals address MIB



## **MIB Agents OutSmarting Osteosarcoma 2024 Grant Program Guidelines**

### **Review Process and Evaluation Criteria (continued)**

priorities, goals and programs, and available funding. The Research Advisory Committee is composed of the MIB Agents Leadership Team, the Family Funds Advisory Council, and the Junior Board Advisory Council President and Vice President.

In the case of an award funded by one Family Fund or individual donor, the sponsoring Family Fund will be included in the programmatic review process.

The two-tier review process results in a robust and collaborative review process that uniquely incorporates patient and family perspectives.

Peer reviewers will use the NIH 9-point rating scale to score the standard NIH criteria:

- Significance
- Investigator
- Innovation
- Approach
- Environment

Given the focus on late translational studies with potential for near-term clinical impact, preliminary data is required.

### **Eligibility**

#### For the OutSmarting Osteosarcoma Research Award

- Principal investigator (PI) must be an independent investigator with experience in translational research.
- Academic ranks of Assistant Professor, Associate Professor, Professor, and research scientists with M.D., D.O., D.V.M., and/or Ph.D. degrees may apply.

#### For the OutSmarting Osteosarcoma Young Investigator Research Award

- Applicants must be within 5 years post fellowship with experience in translational research.
- Academic rank may not exceed Assistant Professor
- M.D., D.O., D.V.M., and/or Ph.D. degrees may apply.



## **MIB Agents OutSmarting Osteosarcoma 2024 Grant Program Guidelines**

### **Eligibility (continued)**

- At the time of application or successful award, the applicant must not hold an NIH independent (R or P) Award. Institutional training grants (K12, T32) are permitted.
- A research mentor(s) must be identified. The application must document the mentor(s) involvement in experimental design and execution and describe a career development and training plan.

### For all OutSmarting Osteosarcoma Awards

- Applicants must be legal US residents engaged by an institution located in the US for the duration of the grant period.
- Per MIB's strict conflict of interest policy, peer reviewers and Scientific Review Committee members may not apply.
- PI must be at a non-profit/academic institution.
- No application limit per institution.
- Only one application per PI as the lead investigator in an award year. Collaborations are accepted.
- Proposals may be for a new or ongoing initiative.
- Funding cannot overlap any funded studies unless the applicant clearly demonstrates that new funding will not duplicate existing support.
- Past winners are permitted to apply after 2 years; proposals must be for a project distinct from their previously funded work.
- Resubmissions are allowed if the proposal addresses peer review feedback from previous submissions and continues to meet the current MIB funding priorities and focus areas.
- Proposals for research utilizing human embryonic stem cells or non-human primates are not eligible. Research with human induced pluripotent stem cells is permissible.
- Applications proposing clinical trials are not eligible, but correlative studies for active trials are accepted and welcome.
- Certification for the protection of human subjects should be obtained for all applicable projects, in accordance with NIH guidelines.



## MIB Agents OutSmarting Osteosarcoma 2024 Grant Program Guidelines

### Reporting Requirements

- The recipient must be available in person to present work underway and completed at the FACTOR 2025 Conference, and may use grant funds for travel to the FACTOR 2025 conference.
- At 6 months post-funding, the recipient must submit a progress report detailing progress on aims as well as a budget report, and host an on-site lab site visit/6-month check-in with MIB Agents representatives.
- At 13 months post-funding, the recipient must submit a progress report detailing progress on aims as well as a budget report. Results of the study funded by an OutSmarting Osteosarcoma grant must be made available to share regardless of the outcome of the research.
- PI must also provide MIB Agents with a one-page layman summary of outcomes to share with the community via the website and present online in the MIB Agents OsteoBites series.
- Any resulting materials (including publications, presentations, posters, press releases, website content, interviews, abstracts, and articles) featuring results of the study funded by a MIB Agents OutSmarting Osteosarcoma grant should acknowledge MIB Agents. Please share copies with [christina@mibagents.org](mailto:christina@mibagents.org).

### Resource Sharing Plan

MIB Agents is dedicated to encouraging collaboration among our community of patients, caregivers, doctors, and researchers. To that end, we require a resource-sharing plan included in the application.

- Please describe the data generated by your research, how it will be FAIR (findable, accessible, interoperable, reusable), and your plan for sharing and dissemination.
- Please describe how the data will be shared both during and after the award. Awardees are required to place data into a publicly accessible repository (e.g., dbGaP for genomics, cBioPortal, Osteosarcoma Explorer). Discuss any intellectual property considerations and how they will be addressed. For any algorithms or tools developed, please discuss what software license will be leveraged and why.
- Finally, please describe your plan to share your research findings with the wider scientific community.



## MIB Agents OutSmarting Osteosarcoma 2024 Grant Program Guidelines

### Payment

- Allowable Costs
  - Travel to FACTOR 2025 (up to \$500 for airfare)
  - Fringe up to 30% of salary requested
  - Publication and meeting-related printing costs
- Unallowable Costs
  - Equipment purchases not included in the original budget
  - The formation of a new organization
  - Planning stages of research
  - Overhead or indirect costs
  - Secretarial/administrative salaries
  - Student tuition
  - Office and laboratory furniture
  - Office equipment and supplies
  - Recruiting and relocation expenses
  - Non-medical services to patients
  - Construction, renovation, or maintenance of buildings/laboratories
  - Professional association membership dues
  - Scientific publication subscriptions
- Payment Schedule
  - Funds are distributed at 3 milestones
    - 50% upon signing of agreement
    - 40% after status report is submitted 6 months after grant start date
    - 10% after status report and end of grant deliverables (written summary and MIB OsteoBites) are submitted 13 months after grant start date
- If work is not completed within the 12 month award period, then unused funds must be returned to MIB Agents unless a no-cost extension has been granted.
- If work is not initiated within 3 months of award start, then the full award amount must be returned to MIB Agents unless a written explanation of delays is submitted to and approved by MIB Agents at least 2 weeks before the 3 month milestone. A no-cost extension is required only if the delays will affect the study end date.
- No-cost extensions may be considered with a written request at minimum 60 days prior to the original end date.
-



## MIB Agents OutSmarting Osteosarcoma 2024 Grant Program Guidelines

### ● Payment (continued)

- Funds are non-transferrable
  - Unused and remaining amounts of \$100+ must be returned to MIB at the end of the grant year.
  - If a Primary Investigator grantee transfers or terminates from his sponsoring institution during the course of the grant award period, the grant will immediately terminate and all monies need to be returned to MIB Agents. Funds can only be transferred to another institution with the written approval of the MIB Agents Research Advisory Committee. The transfer, if approved, will require a close-out financial report from the original institution. The new institution will be required to submit an application along with a budget to be reviewed and approved by the MIB Agents Research Advisory Committee prior to the commencement of this research project at the new institution.

### Other Terms

- Termination: Either party may terminate this agreement by providing three months advance written notice to the other party. MIB Agents may terminate an award in consultation with the MIB Agents Board of Directors.
- Indemnification: Research Institution shall indemnify, defend, and hold harmless MIB Agents and its officers, directors, employees, agents, representatives, successors and assigns (collectively, "Indemnified Party") from and against any and all claims, liabilities, damages, losses, costs, expenses, penalties, fines, interest, demands, actions, suits, settlements, awards and judgments, including without limitation reasonable attorneys' fees and costs ("Claims"), incurred MIB Agents arising from (whether or not alleged by a third party) Research Institution's performance of this Agreement, but only in proportion and to the extent of that such Claims are caused by the intentional misconduct or grossly negligent acts or omissions of Research Institution, its directors, employees, or agents. This provision shall survive the termination of this Agreement.



## MIB Agents OutSmarting Osteosarcoma 2024 Grant Program Guidelines

### Application Submission Requirements

Applications must be submitted online at [ProposalCentral](#), an electronic grant submission system.

- If you are a first-time user in ProposalCentral, click the link: “Need an account?” and complete the registration process.
- If you are already registered in ProposalCentral, access the site and log in with your User ID or email address. If you have forgotten your password, click on “Forgot your password?”
- Once you are logged in to Proposal Central, search for MIB Agents under Grant Opportunities.

For text boxes, ProposalCentral character limits include spaces.

For attachments, please use Arial font, 11 point with a minimum 0.75” minimum margin on all sides.

Please include a header at the top of each page - PI full name, Institution, and Project Title. Please submit uploads as PDFs.

As the MIB Agents collaborative and inclusive two-tier review includes non-scientists from the MIB leadership team and Family Funds, we highlight the importance of providing clear and easily understandable explanations and descriptions.

\*denotes required field

Blue text denotes requirements specific to the OutSmarting Osteosarcoma Young Investigator Research Award

| Field             | Notes  | Requirements       |
|-------------------|--|--------------------|
| Section 1         | Title Page   |                    |
| Project Title*    |  | Max 200 characters |
| Application type* | Select one <ul style="list-style-type: none"> <li>• New</li> <li>• Resubmission</li> </ul> | Select one         |
| Study status*     | Select one: <ul style="list-style-type: none"> <li>• New</li> </ul>                        | Select one         |





## MIB Agents OutSmarting Osteosarcoma 2024 Grant Program Guidelines

|  |  |  |
|--|--|--|
|  | <ul style="list-style-type: none"> <li>Ongoing</li> </ul>  |  |
| For the YI award only, please confirm eligibility* | I am a young investigator within 5 years post fellowship and am applying for the MIB Agents OutSmarting Osteosarcoma Young Investigator Research Award (\$50K)   | Select only to confirm eligibility if applying for the Young Investigator award. |
| Mission statement*                                 | How will this study meet the mission of having the most immediate impact on patient care and make it better for osteosarcoma patients?   | 300 characters   |
| Amount Requested*                                  | Please provide the requested budget.   | Not to exceed \$100,000  |
| Section 2  | Download Templates & Instructions  |  |
| Program Guidelines                                 |  | PDF  |
| Scientific Abstract Instructions                   |  | .DOCX  |
| PI Biosketch (NIH)                                 |  | PDF  |
| Section 3  | Enable Other Users to Access this Proposal   |  |
|  | Please use this section to provide other users access to this application as needed. You may provide administration, edit, or view permissions.  |  |
| Section 4  | Applicant/PI   |  |
|  | Once you create a Proposal Central account, Applicant/PI information will be auto-populated with your professional profile.  |  |
| Section 5  | Institution & Contacts   |  |
|  | Once you select an institution, fields will be auto-populated with the institution profile. In this section, you may also add other institutional contacts: <ul style="list-style-type: none"> <li>Signing official</li> </ul> |  |



## MIB Agents OutSmarting Osteosarcoma 2024 Grant Program Guidelines

|                                     |  |   |
|-------------------------------------|--|---|
|                                     | <ul style="list-style-type: none"> <li>• Department Chair</li> <li>• Financial Officer</li> </ul>  |   |
| Section 6                           | Key Personnel  |   |
|                                     | Please use this section to note all key personnel, other than the applicant, as needed.  |   |
| Section 7                           | Lay Abstract   |   |
| Scientific objective and rationale* | Please describe the scientific objective and rationale.  | 2000 characters   |
| Impact*                             | State the focus area to be studied and describe how the research will make an impact. What types of patients will the research help and how will it help them? What are the potential clinical applications, benefits, and risks? What is the impact on patient outcomes? Describe the likely contributions of this study to advancing the field of osteosarcoma research and/or patient care. Please note any current or announced clinical trials underway that utilize the methods, drugs or treatment in the proposed study. | 2000 characters   |
| Focus area addressed*               | <ul style="list-style-type: none"> <li>• Children, adolescents &amp; young adults</li> <li>• Decreasing toxicities</li> <li>• Genome-informed precision medicine</li> <li>• Immunotherapy</li> <li>• Molecularly targeted therapy</li> <li>• Preventing metastasis</li> <li>• Systemic therapy combinations</li> <li>• Treating recurrent disease</li> </ul>   | Select all the apply  |
| Section 8                           | Scientific Abstract (Document upload)  |   |
|                                     | <p>Please create the scientific abstract as PDF and upload your scientific abstract in this section. For the attachment description, please start the description with the last name of the PI.</p> <p>Please include a header at the top of each page - PI full name, Institution, and Project Title.</p>   | <p>PDF upload</p> <p>Arial font, 11 point with a minimum 0.75" minimum margin on all sides.</p> |



## MIB Agents OutSmarting Osteosarcoma 2024 Grant Program Guidelines

|   |  |   |
|---|--|---|
|   |  | 5pp total max -<br>Max 3pp of text;<br>Max 2pp of images. |
| Investigator*<br><br>For YI award, please<br>also address<br>Mentoring Plan | Describe the PI's background and experience in osteosarcoma research.<br><br>Describe the mentor's role in the experimental design and execution. Describe in detail the plan for career development including strategies for mentorship in pediatric oncology research, continued education, and future research/funding.   |   |
| Objective/Hypothesis*   | State the hypotheses/study questions and overall objective(s) to be reached.   |   |
| Specific Aims*  | State the specific aims of this study.   |   |
| Research Strategy*  | <ul style="list-style-type: none"> <li>Describe the relevant clinical and scientific background that supports the current research plan.</li> <li>Explain the importance of the problem or critical barrier to progress in the focus area that the proposed study addresses.</li> <li>Explicitly state the scientific finding to be translated to the clinic and what the potential clinical impact will be for osteosarcoma patients.</li> <li>Describe how the proposed research allows for an innovative concept to be translated to the clinic. Explain if proposed concepts, approaches, methodologies, instrumentation, or interventions are novel, an improvement, or a refinement, specifying any advantages over existing methods.</li> </ul> |   |



## MIB Agents OutSmarting Osteosarcoma 2024 Grant Program Guidelines

|                       |  |               |
|-----------------------|--|---------------|
|                       | <ul style="list-style-type: none"> <li>Describe the overall strategy to accomplish the aims of the project.</li> <li>Describe methodology, analyses, and how the research aims will be realistically accomplished within the proposed funding period.</li> <li>Provide an account of the investigators' preliminary studies pertinent to the application.</li> <li>Anticipation of potential problems and plans to deal with these is expected.</li> <li>Explicitly state the deliverables that will be generated, and the anticipated time frame for each deliverable.</li> </ul> |               |
| Section 9             | Budget Period Detail   |               |
| Budget*               | <p>Please estimate amounts, to the nearest \$1,000, in the following categories:</p> <ul style="list-style-type: none"> <li>Personnel- identify specific individuals by name (if possible) and role on the project</li> <li>Equipment-identify</li> <li>Supplies - identify</li> <li>Travel (up to \$500 airfare for FACTOR 2025 only)</li> <li>Other</li> </ul> <p>Please note sources and amounts for other past, current and pending grant support for this study.</p> <ul style="list-style-type: none"> <li>Past</li> <li>Current</li> <li>Pending</li> </ul>                 |               |
| Budget Justification* | Please provide a brief written budget justification.   | 1000 char max |
| Section 10            | Budget Summary   |               |
|                       | This page is an auto-calculated summary of the Budget section. No additional information is  |               |



## MIB Agents OutSmarting Osteosarcoma 2024 Grant Program Guidelines

|   |   |  |
|---|---|--|
|   | required on this page.  |  |
| Section 11  | Resource Sharing Plan   |  |
| Resource Sharing Plan*  | Please describe the data generated by your research, how it will be FAIR (findable, accessible, interoperable, reusable), and your plan for sharing and dissemination both during and after the award - such as a publicly accessible repository. Describe protections for privacy and security, including any data governance considerations, and discuss any intellectual property considerations and how they will be addressed. Describe your plan to share your research findings with the wider scientific community. | 1000 characters                              |
| Section 12  | Organizational Assurances   |  |
| Does the proposed project involve human subjects?*            | <ul style="list-style-type: none"> <li>• Yes</li> <li>• No</li> </ul>   | Select one                                   |
| If Yes, status of IRB Approval (If no, select Not Applicable) | <ul style="list-style-type: none"> <li>• Approved</li> <li>• Pending</li> <li>• Exempt</li> <li>• Not Applicable</li> </ul>   | Select one                                   |
| Approval or Pending date                                      |   |  |
| Human subjects Assurance Number (OHRP)                        | This assurance number cannot be entered on this screen – it will appear only if properly entered in the institution profile (for the institution you selected in the institution section of the proposal). If no assurance number appears here, please contact your institution's grants office to have them add the assurance numbers to the institution profile. If you need assistance, contact proposalCENTRAL customer support.  | Auto-populated based on institution profile. |
| Is the proposed study linked to an approved clinical          | <ul style="list-style-type: none"> <li>• Yes</li> <li>• No</li> </ul>   | Select one                                   |



## MIB Agents OutSmarting Osteosarcoma 2024 Grant Program Guidelines

|  |   |  |
|--|---|--|
| trial?*                                    |   |  |
| If Yes, please include the NCT number.     |   | 11 char max  |
| Section 13                                 | Required Attachments  |  |
| Bibliography*                              | Arial font, 11 point with a minimum 0.75" minimum margin on all sides.<br>Please include a header at the top of each page - PI full name, Institution, and Project Title.   | no limit; PDF  |
| Completed W9 form*                         |   | PDF  |
| Institutional IRS Letter of Determination* |   | PDF  |
| PI Bio Sketch (NIH)*                       |   | NIH format - 5pp max; DOCX   |
| Scientific Abstract*                       | Arial font, 11 point with a minimum 0.75" minimum margin on all sides.<br>Please include a header at the top of each page - PI full name, Institution, and Project Title.<br>5pp total max - 3pp max text; 2pp max images encouraged. | PDF<br>5pp max (3pp text/2pp images)   |
|  | Additional Required Attachments for YI Award  |  |
| Mentor Letter of Recommendation            | This letter from the mentor should confirm the role and activities outlined in the mentoring plan.  | PDF - 1pp; Arial font, 11 point with a minimum 0.75" minimum margin on all sides.<br>Please include a header at the top of each page - PI full name, |



## MIB Agents OutSmarting Osteosarcoma 2024 Grant Program Guidelines

|                                     |  |  |
|-------------------------------------|--|--|
|                                     |  | Institution, and Project Title<br>Please submit uploads as PDFs. |
| Mentor Biosketch (NIH)              |  | NIH format - 5pp max; DOCX                                       |
|                                     | Additional Required Attachments for correlative studies and/or studies involving human subjects.   |  |
| Relevant NCT/IRB approval(s)        | For correlative study proposals linked to approved clinical trials please include the protocol and the NCT number or IRB approval notice.  | PDF  |
| IRB and/or IACUC approval letter(s) | For studies involving human subjects, please provide an IRB approval letter and/or an IACUC approval letter or proof of pending submission.  | PDF  |
| Section 14                          | PI Data Sheet  |  |
| Gender                              | <ul style="list-style-type: none"> <li>• Male</li> <li>• Female</li> <li>• Transgender</li> <li>• Non-binary</li> <li>• Other</li> <li>• Prefer not to disclose</li> </ul>   | Select one   |
| Race                                | <ul style="list-style-type: none"> <li>• American Indian or Alaska Native</li> <li>• Asian</li> <li>• Black or African American</li> <li>• Native Hawaiian and Pacific Islander</li> <li>• White</li> <li>• Other</li> <li>• Prefer not to disclose</li> </ul> | Select all that apply  |
| Ethnicity                           | <ul style="list-style-type: none"> <li>• Hispanic or Latino</li> <li>• Not Hispanic or Latino</li> <li>• Prefer not to disclose</li> </ul>   | Select one   |



## MIB Agents OutSmarting Osteosarcoma 2024 Grant Program Guidelines

|                              |   |  |
|------------------------------|---|--|
| Residency & Citizenship Info | <ul style="list-style-type: none"> <li>• Citizen of:*</li> <li>• Permanent resident of:</li> <li>• US citizenship*</li> <li>• US Visa Type</li> </ul>   |  |
| Section 14                   | Validate  |  |
|                              | Click the 'Validate' button below to check for any missing REQUIRED information or files. All missing required information will be listed on the screen. Please correct any missing information before proceeding to the next step - SUBMISSION. Validating the proposal DOES NOT submit the application to the funder. You must proceed to the submission page and click the Submit button there to complete the process.  |  |
| Section 15                   | E-Signature   |  |
| Sign*                        | <p>If I am selected as award recipient, I agree to the following deliverables:</p> <ul style="list-style-type: none"> <li>• In-person presentation of work underway and completed at the FACTOR 2025 Conference</li> <li>• 6-month progress and budget report</li> <li>• Host an on-site lab site visit/6-month check-in with MIB Agents representatives and funders.</li> <li>• 13-month progress and budget report</li> <li>• At 13 months post-funding, results of OutSmarting grant winner's work must be made available to share regardless of the outcome of the research.</li> <li>• One-page layman summary of outcomes to share with the community via the website</li> <li>• Share study outcomes in the MIB Agents OsteoBites series.</li> <li>• Any resulting materials (including publications, presentations, posters, press</li> </ul> | You may print the application from this page with or without attachments |





## MIB Agents OutSmarting Osteosarcoma 2024 Grant Program Guidelines

|  |   |  |
|--|---|--|
|  | <p>releases, website content, interviews, abstracts, and articles) featuring results of the study funded by the MIB Agents OutSmarting Osteosarcoma awards should acknowledge MIB Agents.</p> <ul style="list-style-type: none"> <li>• I certify that the statements herein are true, complete, and accurate to the best of my knowledge. I also provide the required assurances and agree to comply with any resulting terms if I accept an award and in all other respects will be in compliance with the guidelines as outlined in the MIB Agents OutSmarting Osteosarcoma Grant RFA guidelines. I am aware that any false, fictitious or fraudulent statements or claims may subject me to criminal, civil, or administrative penalties. (U.S. Code, Title 18, Section 1001)</li> </ul> |  |
|--|---|--|



## MIB Agents OutSmarting Osteosarcoma 2024 Grant Program Guidelines

### Timeline

|  |                                     |
|--|-------------------------------------|
| RFA Announced  | Thursday, October 26, 2023          |
| Applications Due - Electronic Submission via ProposalCentral | Friday, January 26, 2024 11:59PM ET |
| Award Notification   | Early May 2024                      |
| Grant Dates  | July 1, 2024 - June 30, 2025        |

### Contact

For any questions about the MIB Agents OutSmarting Osteosarcoma grant program, please feel free to contact Christina Ip-Toma by email at [christina@mibagents.org](mailto:christina@mibagents.org).

For technical questions regarding the online submission process, please contact ProposalCentral Customer Service at (800) 875-2562 or via email at [pcsupport@altum.com](mailto:pcsupport@altum.com), during business hours, Monday–Friday, 8:30 AM–5:00 PM (Eastern Time). There is no technical support available on weekends or holidays.

### Additional Resources

Complete online application instructions can also be found at the following links:

- [How to Register your Institution with ProposalCentral \(Grants and Contracts Officials Only\)](#)
- [How to Register as a ProposalCentral user](#)
- [How to Add Other Support](#)
- [How to Add Publications](#)
- [How to Create an Application using ProposalCentral](#)